



On April 17, 2021, the 36th Spring Conference of the Korean Society of Gynecologic Oncology 
(KSGO) was held. Owing to the coronavirus disease 2019 (COVID-19) pandemic, the 
conference was held in a virtual format. With its informative and interesting composition, 
it was a meaningful opportunity for a large number of 372 delegates. A total of 31 speakers 
addressed 13 scientific sessions, and 70 E-poster abstracts were presented. The conference 
was chaired by Dr. Young Tae Kim, the president of KSGO, and was moderated by Dr. Dae 
Woo Kim, the secretary general of KSGO (Fig. 1). The immediate past-president, Dr. Seung 
Cheol Kim and the immediate past-secretary general, Dong Hoon Suh, were awarded 
appreciation plaques (Fig. 2).
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Fig. 1. (A) Opening remark by Dr. Young Tae Kim, President of KSGO. (B) The main venue of the 36th Annual 
Meeting of KSGO. 
KSGO, Korean Society of Gynecologic Oncology.
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In Special Lecture session, Dr. Sudha Sundar from University of Birmingham presented 
how COVID-19 affects the treatment of gynecological cancer patients who require surgery 
(Fig. 3A). At Policy Forum, the topic of evaluating and improving the surgical excellence 
of ovarian cancer was presented and actively discussed by panelists. Three international 
speakers were invited to the plenary session and shared their work and updates in gynecologic 
oncology. In Luncheon symposium session, Dr. Bradly Monk from university of Arizona talked 
about frontline therapy for newly diagnosed advanced ovarian cancer (Fig. 3B). 
In the afternoon, there were 2 online channels. In Channel 1, Focused Plenary sessions 
were dedicated to 10 topics which were selected through strict academic review among 
the previously submitted abstracts. In Channel 2, a collaborative presentation by academic 
organizations closely related to the KSGO was made on topics which are updated recently, 
with masters in the field of pathology, radiation oncology, and chemotherapy (Fig. 4). The 
last, but not the least session of the meeting consisted of three cases of interactive tumor 
board review in which three expert panels discussed updated treatment options with the 
audience who were able to show their opinions by simultaneous electronic votes.
This report summarizes the main topics and highlights of each session.
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Fig. 2. (A) Appreciation ceremony for the immediate past-president, Seung Cheol Kim and the (B) immediate 
past-secretary general, Dong Hoon Suh.
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Fig. 3. (A) Virtual lectures of Invited international speakers, Dr. Sudha Sundar from University of Birmingham, UK 
and (B) Dr. Bradly Monk from university of Arizona, USA.
SPECIAL LECTURE
1.  Impact of COVID-19 on the care of gynecologic cancer patients requiring 
surgery
Dr. Sudha Sundar from Univ. of Birmingham gave a brief overview of the results of COVID 
Surg-gynacecological cancer international study, a multicenter, international, observational 
cohort study, to assess the 30-day COVID-19 infection rate in patients with gynecological 
cancer following elective cancer surgery [1]. From 4,472 patients who underwent 
gynecological cancer surgery, 2.27% were diagnosed with COVID-19 infection and a 1.18% 
mortality rate was observed, which was not significantly higher than the previous database 
before the pandemic. This study provided evidence for performing elective surgery for 
gynecologic cancer in the era of the COVID-19 pandemic.
2.  COVID-19 pandemic and cancer management, clinical trial, and vaccination
Dr. Soo Jin Park from Seoul National University Hospital presented on cancer patient 
treatment, clinical trials, and vaccination during the COVID-19 era. In the case of cancer 
patients with confirmed COVID-19, one to four weeks of postponement may be considered 
for gynecological cancer surgery, and in the case of radiation therapy, a treatment pause 
should be considered. Physicians should consider holding chemotherapy for at least 10 days, 
and it is recommended to use granulocyte colony-stimulating factor after fever disappears. It 
is recommended that clinical trials continue in most situations when it is judged that benefits 
outweigh the risks according to the sponsor's guidelines.
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Fig. 4. Scenes from the Meeting of Korean Society of Gynecologic Oncology.
POLICY FORUM: SURGICAL QUALITY OF OVARIAN CANCER
1. Surgical quality of ovarian cancer: how to evaluate and improve?
Dr. Suk-Joon Chang from Ajou University gave an important lecture on the quality evaluation 
and improvement of ovarian cancer surgery. Although the role of surgery is important in 
ovarian cancer treatment, it is difficult to evaluate the quality of surgery objectively in the 
real clinical settings. Recently, the European Society of Gynaecological Oncology (ESGO) has 
created a program to certify institutions with high quality of surgery for advanced ovarian 
cancer and is attempting to establish objective authentication using 10 quality indicators 
[2]. The 10 certification indicators include QI 1: Rate of Complete Surgical Resection; QI 
2: Number of Cytoreductive Surgeries Per Center and Per Surgeon Per Year; QI 3: Surgery 
Performed by a Gynecologic Oncologist or a Trained Surgeon Specifically Dedicated 
to Gynecological Cancer Management; QI 4: Center Participating in Clinical Trials in 
Gynecologic Oncology; QI 5: Treatment Planned and Reviewed at a Multidisciplinary Team 
Meeting; QI 6: Required Pre-operative Workup; QI 7: Pre-operative, Intra-operative, and 
Post-operative Management; QI 8: Minimum Required Elements in Operative Reports; QI 
9: Minimum Required Elements in Pathology Reports; and QI 10: Structured Prospective 
Reporting of Post-operative Complications.
PLENARY SESSION I
1. Drug repositioning for ovarian cancer targeting mevalonate pathway
The first plenary session was opened by Dr. Yusuke Kobayashi from Keio University. Dr. 
Kobayashi presented how statins, one of the most frequently prescribed medications for 
dyslipidemia, may help treat ovarian cancer by targeting the mevalonate pathway. This was 
introduced in the concept of drug repositioning, which is increasingly becoming an attractive 
proposition because it involves the use of compounds that have already been completed 
the evaluation of toxicity profiles [3]. Data from The Cancer Genome Atlas (TCGA) showed 
increased activity of the mevalonate pathway in ovarian cancer patients whereas the pathway 
was consistently down-regulated in normal samples [4]. In in vivo experiments with ovarian 
cancer cell lines, a number of mevalonate pathway inhibitors demonstrated concentration-
dependent inhibitory effects on cell proliferation [5]. This inhibitory effect was also shown 
by statin, HMG-CoA reductase inhibitor, and was augmented when given with paclitaxel 
or carboplatin together, showing synergistic inhibitory effects. Not only in in vivo studies, 
but also in animal models, mogp-TAg transgenic mouse models, which mimic serous tubal 
intraepithelial carcinoma (STIC), demonstrated decreased tumor weights after they were 
given statins. These inhibitory effects of statins were most significantly demonstrated in 
serous and clear cell ovarian carcinomas among others. The study concluded that statins 
may have anti-tumor activity against epithelial ovarian cancer, especially serous and clear cell 
carcinomas, and showed potential benefits that may be derived from its drug repositioning.
2.  Novel nanomedicine for epithelial ovarian cancer: cathepsin B-cleavable 
peptide-conjugated doxorubicin prodrug
The second plenary session was carried out by Dr. Soo-Young Jeong from Hallym University. 
Dr. Jeong presented how nanoparticles may help deliver anti-cancer drugs in a more efficient 
way and thereby improve its therapeutic efficacy. Cathepsin B is a member of lysosomal 
cysteine proteases and involves in intracellular proteolysis. It is known to be overexpressed 
in various types of cancer and is recently utilized as a selective diagnostic marker [6]. Her 
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research team developed carrier-free nanoparticles of cathepsin B-cleavable peptide that 
conjugates with doxorubicin prodrug. When administered to HeyA8 and HeyA8-MDR cell 
lines, doxorubicin that is conjugated with cathepsin B-cleavable peptide was shown at a high 
concentration in intracellular nucleus in HeyA8 cell lines but was distributed in cytoplasm 
in normal cell lines on confocal microscopy. On the other hand, unconjugated doxorubicin 
was concentrated in the nucleus both in cancer cell lines and normal cell lines. This suggests 
the selective distribution of nanoparticle-conjugated anti-cancer drugs in different cell lines, 
which may provide means to reduce unwanted cellular toxicity in normal cells. This was also 
demonstrated by decreased cell viability in both cancer cells and normal cells when they 
were treated with unconjugated doxorubicin, whereas only cancer cells illustrated decreased 
viability when treated with doxorubicin conjugated with cathepsin B-cleavable peptide. The 
cell viability of normal cells remained steady. This desired accumulation of nanoparticle-
conjugated doxorubicin was also demonstrated in animal model studies. When evaluated 
with fluorescent microscope on orthotopic ovarian cancer mouse models with HeyA8 cell 
lines, doxorubicin conjugated with cathepsin B-cleavable peptide was concentrated in 
tumor tissues at almost 3 to 4 times higher concentrations than unconjugated doxorubicin. 
The therapeutic efficacy of conjugated doxorubicin remained similar in comparison to 
unconjugated doxorubicin. In summary, the study demonstrated how novel nanoparticles 
may allow precise targeting of tumor cells, which consequently achieves enhanced drug 
delivery and also reduces side effects and drug resistance.
3.  Multi-Omics and therapeutically applicable research of ovarian cancer 
(MOTAROC)
The next session was presented by Dr. Gang Chen from Tongji Medical College in China. 
He introduced various laboratory techniques from a number of landmark multi-omics 
studies. He termed the concept of applying these techniques as MOTAROC. Moving from the 
traditional treatment paradigm of using non-selective cytotoxic agents to selective, genomic 
and targeted agents for the treatment of ovarian cancer patients, scientists have been able to 
achieve not only the enhancement of therapeutic effects but also the prolongation of patient 
survival. Studies utilizing organoids platform, 3-dimentional microfluidic culture, patient-
derived xenograft, reverse phase protein microarray (RPPA) are among the examples of such 
endeavors. In order to benefit from such techniques, precise molecular characterization of 
patient tumor such as histopathologic, genomic, transcriptomic, proteomic, immunologic 
and metabolomics analysis should be preceded. By accomplishing such characterization, 
scientists were able to identify one of the mechanisms by which resistance to poly-ADP ribose 
polymerase (PARP) inhibitors develop. Studies published in Science Translational Medicine in 
2017 and in Cancer Cell in 2018 showed that specific molecular signaling pathway mediates 
the development of resistance to PARP inhibitors [7,8]. They found that PARP inhibitors 
and RAS/mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor synergistically 
suppress the growth of tumor cells in epithelial ovarian cancer. Furthermore, researchers 
have been able to achieve the identification of the relationship between homologous 
recombination deficiency (HRD) and bromodomain containing 4 (BRD4) proteins and 
found the inhibition of BRD4 induces HRD regardless of the mutational status in BRCA 1/2, 
TP53, RAS, or BRAF. This warrants further investigation on the potential usage of BRD4 for 
ovarian cancer patients with homologous recombination proficiency. As PARP inhibitors are 
now becoming an important axis in the treatment of ovarian cancer, such studies provide 
important clues to understand the relationship between PARP inhibitors and HRD status, 
which is invaluable in the current time.
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PLENARY SESSION II
1.  Risk of adverse obstetric outcomes in patients with a history of 
endometrial cancer: a population-based cohort study
Dr. Seung-Hyuk Shim from Konkuk University presented the results of his nation-wide 
cohort study on the relationship between fertility-sparing treatment for early endometrial 
cancer and obstetric outcomes. In order to perform his analysis, he used the data from the 
Korean National Health Insurance Service. A total of 246 women who had been treated in 
any form of progestin therapy for early endometrial cancer between 2009 and 2016 prior to 
delivery were identified. These women were compared to 3.2 million women who delivered 
without any history of endometrial cancer during the same period of time. He identified that 
those with the history of progestin therapy for endometrial cancer had higher relative risk 
ratios for multifetal gestation, delivery by cesarean section, and preterm delivery compared 
to those women without endometrial cancer. However, the history of endometrial cancer 
treatment did not increase the risk of preeclampsia, gestational diabetes or any other 
adverse obstetric outcomes. When sensitivity analysis excluding multifetal gestation was 
performed, the authors found that the risk of preterm birth was not increased. It also revealed 
similar rates of preeclampsia, gestational diabetes, placenta previa, placenta accrete and 
the incidence of vacuum delivery. In conclusion, the study showed the increasing trend of 
childbirth in endometrial cancer patients after fertility-sparing treatment and comparable 
obstetric outcomes between those who had undergone fertility-sparing treatment and those 
who were never diagnosed with endometrial cancer. The researchers also concluded that the 
higher risks of multiple gestation and cesarean delivery were presumably attributable to the 
use of artificial reproductive techniques and not the history of endometrial cancer itself.
2.  Comparisons of survival between bevacizumab vs. olaparib in platinum-
sensitive, relapsed ovarian cancer (KGOG 3052)
The next session was presented by Dr. Se Ik Kim from Seoul National University on the 
multi-center study KGOG 3052, in which 10 institutions in South Korea had participated. 
The researchers retrospectively analyzed the survival outcomes of olaparib vs. bevacizumab 
treatment in patients with relapsed high-grade serous carcinoma of ovary. The included 
patients were those with BRCA 1/2 mutation (germline or somatic), and who received platinum-
based combination chemotherapy for their second-line treatment (platinum-sensitive 
recurrence). A total of 29 patients who received second-line platinum-based chemotherapy 
including bevacizumab (Bevacizumab group) and 119 patients who received platinum-based 
chemotherapy doublets without bevacizumab (Olaparib-intent group) were identified. Among 
the Olaparib-intent group patients, 83 patients actually received olaparib maintenance after 
chemotherapy. Multivariate analysis revealed that the Olaparib-intent group had longer 
progression-free survival (PFS) (adjusted hazard ratio [aHR]=0.566; 95% confidence interval 
[CI]=0.341–0.940; p-value=0.028) compared to the Bevacizumab group. The overall survival 
(OS) did not differ between the 2 groups. After conducting propensity score matching for 
controlling the disease stage, surgical outcomes after the first cytoreductive surgery, treatment-
free interval, serum CA-125 levels at first recurrence and surgical outcomes after the second 
cytoreductive surgery, intention to Olaparib maintenance was still an independent favorable 
prognostic factor for PFS. As the proportion of olaparib users in the Olaparib-intent group 
increased, the median PFS further increased while aHR decreased. The authors concluded that 
intention to olaparib maintenance and actual use of olaparib was associated with significantly 
better survival outcomes than bevacizumab in second-line treatment of BRCA-mutated, 
platinum-sensitive, relapsed high-grade serous carcinoma of ovary.
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3.  Machine learning-based predictive model for parametrial invasion in 
patients with early-stage cervical cancer
In the next session, Dr. Kittipat Charoenkwan from Chiang Mai University introduced a 
computational model for identification of parametrial invasion in women with early-stage 
cervical cancer. Parametrial invasion of tumor is reported to occur in only 5% to 25% in 
early-stage cervical cancer [9]. Performing radical hysterectomy may not necessarily yield 
survival benefits in those women without parametrial tumor invasion. Therefore, accurate 
prediction of parametrial invasion prior to surgical treatment may prevent the performance 
of unnecessary aggressive radical hysterectomy. Dr. Charoenkwan and colleagues developed 
a novel machine learning-based predictive model by analyzing potential clinicopathological 
risk factors. The authors named iPMI-Econ model that included age, parity, human 
immunodeficiency virus (HIV) infection status, menopausal status, underlying disease, prior 
conization, tumor size, stage, and histology, which achieved an area under the curve (AUC) 
of 0.943. The authors further developed iPMI-Power model that included pelvic lymph node 
metastasis status and uterine corpus metastasis status in addition to the iPMI-Econ model, 
which achieved an AUC of 0.972. By developing a relatively simple mathematical model using 
easily-obtainable clinicopathologic information prior to surgery, the authors were able to 
build a learning algorithm that may be applied in the clinical settings with good performance 
to predict parametrial invasion in early-stage cervical cancer.
LUNCHEON SYMPOSIUM
1. Frontline Therapy for newly diagnosed advanced ovarian cancer
In this session, Dr. Bradly Monk from university of Arizona talked about frontline therapy 
for newly diagnosed advanced ovarian cancer. He began the lecture with the GOG 218 
trial of adding bevacizumab with chemotherapy and in the maintenance phase. Dr. Monk 
explained how they came to design the GOG 218 [10]. The study revealed no survival 
differences observed with addition of bevacizumab compared chemotherapy alone [10]. 
Finally, they published it in the New England Journal in 2011, and then ultimately got an 
Food and Drug Administration (FDA) approval in June of 2018. It took seven years after 
the New England Journal publication to get FDA approval because unlike Europe, where they 
understood the value of PFS, the US regulators felt that OS needed to be the endpoint. 
Finally, U.S. FDA has accepted PFS is the endpoint for monitoring clinical benefits, but 
it had to be clinically meaningful and at the minimum had to be 6 months. We can see 
update in September of 2019 Journal of Oncology; there was no survival advantage [11]. BRCA 
1/2, homologous recombination repair were not predictors of bevacizumab activity [11]. 
So, we did chemotherapy first. We did Bevacizumab second, and then we entered the era 
of PARP inhibitors. Dr. Monk and his colleague have tried to identify biomarkers of PARP 
sensitivity. They went on to try to identify the beyond-BRCA mutations, which not only 
included mutations, but epigenetic silencing and promoter methylation, to get the complete 
picture of who might benefit from a PARP inhibitor. And he said that probably the best 
assay is myChoice CDx®, because it looks at the genomic scar, the result of the homologous 
recombination deficiency with the score. He explained that the first thing he wanted you 
to focus on is BRCA 1, BRCA 2, not the same. Moreover, the molecular signature of BRCA 
mutation, homologous repair deficiency and homologous repair proficiency is really 
important when all patients were sensitive to platinum. It is really important to use the 
biomarker and certainly number of lines of therapy, so the earlier we can integrate these.
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SOLO-1 study revealed that the use of maintenance with olaparib gave a subsequent advantage in 
regard to PFS with newly diagnosed advanced ovarian cancer and BRCA mutation [12]. He said 
that SOLO-1 study really changed the flow because we really have not been good at testing the 
tumor, the somatic mutations, but it changed the workflow. However, he pointed that SOLO-1 was 
BRCA only, 25% of ovarian cancers. Therefore, they wanted all-comers and they wanted to fix the 
dosing issue. The result of PRIMA study is that among patients with newly diagnosed advanced 
staged ovarian cancer with a previous response to platinum, those who received niraparib had 
better PFS than placebo group, regardless of the status of homologous-recombination deficiency 
[13]. On April 29th 2020, this was approved by FDA for all-comers. Next, he moved to PAOLA-1 
study [14]. He said that PAOLA-1 is a very different study. Number one, it was an investigator-
initiated study. And the primary endpoint was all-comers. The HRD endpoint was not an 
endpoint. The HRD endpoint was not balanced between the arms, and it created a lot of concern 
about how this is going to be viewed as regulators, but it was sort of submitted at the exact same as 
PRIMA, and there was no PRIMA arm here. Unlike PRIMA study, where there is an impact in the 
HR proficient group, there is absolutely no benefit in the homologous recombination proficient 
benefit of PAOLA-1 [14]. Despite higher discontinuing rate, the FDA approved on May 8th 2020, 
just 10 days after the April 29th approval of PRIMA. At the end of the session, he showed the Monk 
algorithm [15] and emphasized that we should do germline testing and probably a panel, and we 
should also do HRD testing if germline BRCA is wild type.
FOCUSED PLENARY I
1.  Immunohistochemical and genetic characteristics of invasive stratified 
mucin-producing carcinoma of the uterine cervix
The next session was presented by Dr. Eunhyang Park from Yonsei University. Dr. Park 
introduced invasive stratified mucin-producing carcinoma (ISMC), a recently described entity 
of human papilloma virus (HPV)-associated endocervical adenocarcinoma. She and her 
colleagues investigated the immunohistochemical expression of cervical epithelial cell markers, 
stemness markers, and epithelial-mesenchymal transition (EMT) markers in 10 ISMCs. It was 
found that ISMC was significantly associated with larger tumor size (p-value=0.011), more 
frequent lymphovascular invasion and lymph node metastasis (p-value<0.001), higher disease 
stage (p-value=0.022) and a tendency for worse clinical outcomes (p-value=0.056) compared to 
other HPV-associated subtypes. ISMC also showed distinct patterns of immunohistochemical 
properties. It also exhibited frequent STK11, MET, FANCA, and PALB2 mutations compared 
to the conventional cervical carcinomas, and the genes related to EMT and stemness were 
frequently altered. The authors concluded that ISMC is an aggressive HPV-associated 
endocervical adenocarcinoma with stemness and EMT properties and distinct genetic 
alterations. They also recommended the utilization of PAX8, CK5/6, and p63 as diagnostic triple 
biomarkers for ISMC based on their analysis on immunohistochemical properties.
2.  Circulating tumor cells as a predictive marker for treatment monitoring of 
ovarian cancer patients
The next session was presented by Dr. Seungmee Lee from Keimyung University on the 
potential usage of circulating tumor cells as a predictive marker for treatment monitoring of 
ovarian cancer patients. Dr. Lee prospectively analyzed 49 serial blood samples at multiple 
time points from 13 women with epithelial ovarian cancer. Dr. Lee and colleagues were able 
to isolate circulating tumor cells from the blood of ovarian cancer patients with the mean and 
median count of 20.2 and 6.0 per sample, respectively. During the median follow-up of 22.7 
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months, circulating tumor cell count and serum CA-125 levels showed a high concordance 
with directional change (increasing 71.4% and decreasing 75.0%). When compared to serum 
CA-125 levels, circulating tumor cell count further demonstrated a significant association 
with the clinical status of the patients by showing higher sensitivity (100% vs. 60.0%), 
positive predictive value (55.6% vs. 42.9%), and negative predictive value (100% vs. 87.5%). 
The authors concluded that circulating tumor cell count was better associated with treatment 
response and recurrence in comparison to serum CA-125 levels.
3.  C-peptide prevents hyperglycemia-induced transglutaminase 2 (TGase2) 
activation in ovarian cancer cells
Dr. Yung-Taek Ouh of Kangwon National University School of Medicine presented an 
experimental study on the role of C-peptide in an ovarian cancer cell line. Diabetes mellitus 
(DM) is a poor prognostic factor in patients with ovarian cancer [16-19]. The increased 
levels of TGase2 and reactive oxygen species (ROS) found in patients with DM may promote 
migration and invasion of cancer cells [20,21]. SKOV3 cells were treated with C-peptide, 
which is deficient in type 1 DM and is known to play an important role in suppressing 
diabetic complications [22-25], to determine the correlation between TGase2 and ROS. 
TGase2 was activated by high glucose-induced ovarian cancer by sequential elevation of 
intracellular Ca2+ and ROS levels. C-peptide inhibited high-glucose-induced ROS generation 
and TGase2 activation. High glucose also promoted the epithelial to mesenchymal transition 
markers including increased N-cadherin and vimentin, which was prevented by C-peptide. 
Furthermore, C-peptide inhibited cell migration and invasion induced by high glucose. This 
study revealed the pathophysiology of ovarian cancer due to hyperglycemia and, in turn, 
showed that C-peptide may serve as a new treatment for patients with ovarian cancer and DM.
FOCUSED PLENARY II
1.  Accuracy of HPV tests using urine samples versus clinician-collected 
samples for the detection of cervical precancer: a meta-analysis
Dr. Hyun Woong Cho of Korea University College of Medicine published a meta-analysis 
comparing the accuracy of a human papillomavirus (HPV) test determined using self-
collected urine and physician-collected samples to detect pre-cancerous lesions in the cervix. 
Twenty-one studies were included in the meta-analysis. The HPV test conducted using 
urine samples was 14%–21% less sensitive for detecting lesions of CIN2 or higher than that 
conducted using physician-collected samples; there was no difference in specificity. The 
relative sensitivity was significantly lower in the HPV test conducted using urine samples 
than that conducted using physician-collected samples; however, there was no difference in 
the relative specificity. The urine sample-based HPV test using a polymerase chain reaction 
(PCR)-based assay had comparable sensitivity to the physician-collected sample-based HPV 
test. Women who refuse or are reluctant to participate in a cervical cancer screening program 
owing to the COVID-19 pandemic might find that a self-administered urine sample-based 
HPV test using PCR analysis is an acceptable alternative.
2.  Dynamics of fecal microbiota with and without invasive cervical cancer 
and its application in early diagnosis
Dr. Yoon Hee Lee of Kyungpook National University School of Medicine presented a study 
examining the correlation between early cervical cancer and the fecal microbiome. The 
authors also sought to determine if the fecal microbiome could be used as a biomarker using 
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machine learning technique. Fecal DNA data were obtained from 17 patients with cervical 
cancer and 29 healthy controls using 16s rRNA gene sequencing. Prevotella was abundant in 
patients with cervical cancer, while Clostridium was abundant in healthy controls. There was 
a between-group difference in microbiome composition; healthy control women had a more 
complex symbiotic network than patients with cervical cancer. Through machine learning, 
seven microorganisms were identified as differentiating factors between the 2 groups; a 
heat map was deduced that showed the top predictors to be Prevotella and Turicibacter. The 
predictive model had good diagnostic value with an AUC greater than 0.9.
3.  Concerns regarding the long lead time following a confirmatory test after 
an abnormal Pap test result in the COVID-19 era
Dr. Miseon Kim of CHA University School of Medicine presented a study that examined the 
lead time to confirmatory test after abnormal screening Pap test during the COVID-19 era. 
From January 2019 to December 2020, 1,144 patients with abnormal pap smear results who 
underwent colposcopy were included in the study. The lead time to colposcopy from the Pap 
test was examined between 2019 and 2020 was compared. Dr. Kim and colleagues could not 
determine any difference in the lead time before and after the emergence of COVID-19.
FOCUSED PLENARY III
1.  Determining the extent of lymphadenectomy in patients with endometrial 
cancer
Dr. Wonkyo Shin of the National Cancer Center studied the scope of lymphadenectomy in 
patients with endometrial cancer. The authors sought to determine if there were clinical 
factors that could determine the scope of lymphadenectomy or any differences in risk factors 
depending on the location of lymph node metastases. The study included 468 patients 
with early endometrial cancer and was conducted from January 2016 to December 2018. 
Para-aortic lymphadenectomies were performed based on multiple factors, including each 
patient's preoperative histology, extent of cervical invasion, and cancer grade. Depending 
on the risk, performance of up to an aortic lymph node resection had a good survival rate. 
There was no clinical difference relative to the location of the lymph node metastases. This 
presentation emphasized the importance of risk-group evaluation for determining the scope 
of lymph node resection in patients with early-staged endometrial cancer.
2.  Nomogram for microscopic lymph node metastasis in patients with 
surgically staged endometrioid endometrial cancer
Dr. Tae-Wook Kong of Ajou University School of Medicine introduced a nomogram that 
predicted microscopic lymph node metastases. Such metastases are difficult to identify 
on preoperative imaging of endometrioid endometrial cancer. This study included 338 
patients without lymph node metastasis on preoperative imaging who underwent pelvic 
and para-aortic lymphadenectomy. Of these patients, 9.8% had microscopical lymph node 
metastases. Nomogram construction included age, CA-125 level, preoperative tumor grade, 
myometrial invasion on magnetic resonance imaging, cervical stromal invasion, parametrial 
invasion, and lesion size as variables. The concordance index of the nomogram was 0.860 
(95% CI=0.788–0.927), and calibration plots showed a good match between the observed 
and nomogram-predicted probabilities. This study provides important information to help 
determine whether to perform lymphadenectomy, as it allows nomogram-based prediction of 
microscopical lymph node metastases.
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3.  Incidence and risk factors of venous thromboembolism (VTE) in patients 
with cervical cancer using the Korean National Health Insurance data
Dr. Banghyun Lee of Inha University School of Medicine presented a study identifying 
the incidence rate of VTE and its risk factors in patients with cervical cancer using South 
Korea's Health Insurance Review and Assessment Service data. Between 2009 and 2018, 
49,514 patients with cervical cancer were included. The incidence of VTE was 115 per 10,000 
patients. The average age of patients with VTE was 58 years, which was higher than that of 
patients without VTE. Patients who received chemotherapy as the primary treatment had 
the highest incidence of VTE; however, the incidence decreased over time. There was a 
higher frequency of VTE when platinum was included in the chemotherapy, and there was no 
difference associated with bevacizumab use. Dr. Lee and the chair of this session emphasized 
that the risk of VTE should be evaluated in patients with cervical cancer and, if necessary, 
prophylactic treatment should be initiated.
4.  Survival analysis of chemoradiotherapy versus only chemotherapy in stage 
III endometrial cancer: a multicenter study
Dr. Jigeun Yoo of the Catholic University of Korea presented a multicenter retrospective study 
that compared chemotherapy combined with radiation therapy and chemotherapy alone in 
stage III endometrial cancer. The study examined OS and toxicity profiles of 80 patients who 
received 6 cycles each of full-dose chemotherapy and external beam radiation therapy (CRT) 
and 53 patients who received chemotherapy alone. There was no significant difference in 
3-year disease-free survival (DFS), but in IIIc endometrioid histology, the CRT-enforced group 
showed better 3-year DFS. Grade 4 neutropenia and thrombocytopenia were more frequent in 
the CRT group.
Distillation session was held at the end of the presentation for the first time at this 
conference. It provided attendees with an excellent opportunity to organize the background 
and results of each session and to discuss future directions.
KSGO-KSP JOINT MEETING
1.  World Health Organization (WHO) classification of female genital tumors, 
5th ed.
Dr. Cheol Lee form of Department of Pathology, Seoul National University Hospital gave a 
summary of the 5th edition of the WHO classification of female genital tumors that have 
recently been revised. It was characterized by reflecting molecular pathological classification in 
addition to the conventional morphological classification. In cervical cancer, HPV infection has 
established itself as a major axis of classification. HPV independence is rare but has been known 
to have a poor prognosis. In ovarian cancer, it is worth noting that low-grade serous carcinoma 
and high-grade serous carcinoma were classified as completely separate diseases with no 
evidence of transition. In endometrial cancer, carcinosacoma was classified as a carcinoma.
2.  European Society of Medical Oncology-European Society of Gynaecological 
Oncology (ESMO-ESGO) new guideline for endometrial cancer: focusing on 
molecular classifier
Dr. Han Byul Cho from Yonsei University gave a lecture on the new aspects of ESMO-
ESGO classification of endometrial cancer. The molecular classification was attempted in 
the revised guideline. However, complete molecular classification using whole-genome 
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sequencing is difficult to be generalized due to the high cost and inconvenience to use fresh 
frozen tissue. Therefore, in the newly proposed ProMisE molecular classification, formalin-
fixed, paraffin-embedded and immunohistochemical can be used. In the ESMO-ESGO new 
guideline, the diagnosis algorithm proposed by Vermij and colleagues was adopted, and 
tumors were classified by three IHC markers (p53, MSH6, PMS2) and somatic mutation 
analysis of polymerase epsilon [26]. Through this, it is classified into four risk groups: Low/
Intermediate/High-intermediate/High.
KSGO-KOSRO JOINT MEETING
1. Adjuvant therapy for postoperative cervical cancer
Dr. Yong Bae Kim from Department of Radiation Oncology, Yonsei University College 
of Medicine, gave a summary of radiation therapy (RT) for cervical cancer. Concurrent 
chemoradiotherapy (CCRT) with the addition of cisplatin has been proven in several clinical 
trials to be an effective cervical cancer treatment. RTOG-0724, which compares the effects of 
cisplatin and carboplatin/paclitaxel during CCRT in high-risk groups, and GOG-263, which 
compares RT and CCRT in moderate-risk groups, are ongoing. Surgery is not recommended 
in most cases for newly revised cervical cancer stage IB3, i.e., 4 cm or larger tumor. In 
addition, if cancer metastasis is confirmed on the frozen section examination for LN biopsy 
during surgery, it is better to stop the operation and save the uterus to raise the small bowel 
at the time of radiotherapy. Also, since it is expected that the function of the ovary will be lost 
when exposed to 3 grays or more radiation, appropriate judgment is required.
2. Intraoperative detection of lymph node metastasis: hysterectomy or not
Dr. Won Duk Joo from CHA University gave a lecture on the diagnosis of lymph node metastasis 
during surgery. In cervical cancer, as the International Federation of Gynecology and 
Obstetrics (FIGO) stage revised in 2018 included lymph node metastasis, the role of resection 
became important, accordingly, the National Comprehensive Cancer Network guidelines 
recommend surveillance lymph nodes. To avoid complications, systemic lymphadenectomy is 
recommended to be performed only when cancer metastasis is detected in the sentinel lymph 
node using substances such as indigo carmine, indocyanine green (ICG), and technetium 
(99mTc). According to a trial called ABandoning RAd hyst in cerviX cancer (ABRAX), there was 
no survival benefit in completing (radical) hysterectomy compared with abandoning surgery 
when intraoperative metastatic lymph node was detected.
KSGO-KSMO JOINT MEETING
1. Immune checkpoint inhibitors in recurrent gynecologic cancer
Dr. Seung-Hyuk Shim from Konkuk University summarized the role of immune checkpoint 
inhibitors in recurrent gynecologic cancer. In endometrial cancer, the ratio of deficient 
mismatch repair and microsatellite instability-high tumor is about 30%, and programmed 
cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) expression are relatively 
high. Also, tumor-infiltrating lymphocytes are present, which makes it an ideal target for 
immunotherapy. Thus, the combination of anti-vascular endothelial growth factor along with 
immuno-oncology has shown promising results. In contrast, recurrent cervical and ovarian 
cancers have shown disappointing results in several clinical studies. There is an urgent need 
to discover biomarkers that can select the right patient for the treatment.
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2. Candidate biomarkers for immune checkpoint inhibitors
Dr. Sook-Hee Hong from Department of Internal Medicine, Catholic University gave a 
presentation on possible biomarker candidates for the immune checkpoint inhibitors (ICIs). 
Currently, ICIs are not widely used in gynecological cancer, except for endometrial cancer. 
Gynecological cancer has a low expression of tumor mutational burden and PD-L1, so a 
more detailed strategy is needed. The T cell-inflamed gene expression profile is also worth 
considering as a candidate by referring to the case of other carcinomas, but no consensus has 
been made for the gene mutation that can predict the conditions. Therefore, it is necessary 
to study the components of the tumor microenvironment and the molecular mechanisms 
driving these changes, in addition to the existing tumor-focused studies.
TUMOR BOARD
The last session of the meeting consisted of three cases of interactive tumor board review in 
which three expert panels (Dr. Jae Man Bae from Hanyang University, Dr. Dae Gy Hong from 
Kyungpook National University, and Dr. Jeong Yeol Park from Ulsan University) discussed 
possible treatment options with the audience who were able to show their opinions by 
simultaneous electronic votes.
The first case was a 72-year-old woman with stage IVB high-grade serous carcinoma of the 
ovary. Opinions regarding the management of the patient were asked sequentially to the 
audience, and the panels discussed each treatment choice with up-to-date evidence from 
clinical trials. For this patient, the audience preferred to initiate treatment by diagnostic 
laparoscopy to determine primary debulking surgery versus neoadjuvant chemotherapy 
(52% of the audience's choice) in consideration of her old age and advanced disease status. 
They also wanted to perform tests for germline BRCA and HRD (50% of the audience) at 
the initial stage of the treatment. The tests resulted in BRCA wildtype and HRD negative. 
Consequently, the audience chose platinum-based chemotherapy with bevacizumab 
followed by bevacizumab maintenance (56% of the audience). Unfortunately, the patient 
recurred after 12 months of platinum-free interval. The recurred lesion was localized in the 
liver parenchyma on radiology. Most of the audience (60%) chose to perform secondary 
cytoreduction followed by platinum-based chemotherapy and PARP inhibitor maintenance. 
Despite the treatment efforts, the patient developed platinum resistance and follow-up tests 
revealed HRD positive and somatic BRCA mutation. The audience showed the preference of 
using PARP inhibitors (55%) as her next treatment choice.
The next case was a 67-year-old woman who underwent laparoscopic staging operation 
and found to have FIGO stage IIIC1 serous carcinoma of the endometrium. The 
immunohistochemistry revealed p53 abnormality. The audience chose microsatellite instability 
(MSI) test (46%) as the most helpful test for her optimal treatment followed by human 
epidermal growth factor receptor 2 (HER2) expression test (28%). The HER2 expression turned 
out to be weak positive (1+). Despite the weak positivity of HER2 expression, the audience chose 
the use of trastuzumab in addition to the use of platinum-based chemotherapy (47%). The 
next frequent choice of treatment was the PORTEC-3 trial regimen (cisplatin with concurrent 
radiotherapy followed by paclitaxel and carboplatin) (34%).
The last case was a 38-year-old woman with radiologic stage of IB2 squamous cell carcinoma 
of the cervix. The audience answered that they would perform open radical hysterectomy 
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(67%) for the initial treatment. However, the patient underwent laparoscopic radical 
hysterectomy during which frozen pathology revealed metastatic pelvic lymph nodes. The 
question was asked to the audience whether to carry on radical hysterectomy. The majority 
of the audience chose to perform paraaortic lymph node staging and abandon radical 
hysterectomy for subsequent concurrent chemoradiation therapy (38%). Other opinions 
included the continuation of laparoscopic radical hysterectomy (29%), discontinuation of 
radical hysterectomy without paraaortic lymph node staging (24%) and conversion to open 
radical hysterectomy (9%). The ABRAX study was introduced by Dr. Jae Man Bae which 
demonstrated similar survival outcomes between those who completed radical hysterectomy 
and those who abandoned radical hysterectomy after finding pelvic lymph node metastasis 
intraoperatively [27].
All 3 cases captured the most current issues of each malignant disease and provided an 
opportunity to review the corresponding evidence from recent clinical trials. The use of PARP 
inhibitors in advanced epithelial ovarian cancer, utilization of the new molecular classification 
of endometrial cancer, and the implementation of the results from the laparoscopic approach 
to cervical cancer (LACC) trial into the clinical setting are all ongoing issues of the current 
research field. This tumor board session was different from previous conventional format of 
conference meetings and thereby earned considerable favors from the audience.
AWARDS
The honorable Shin-Poong-Ho-Wol Awards of the 2021 KSGO annual meeting went to Dr. 
Seung-Hyuk Shim of Konkuk University and Jigeun Yoo of Catholic University for their 
presentation on Risk of adverse obstetric outcomes in patients with a history of endometrial cancer: a 
population-based cohort study and Survival analysis of chemoradiotherapy versus chemotherapy alone 
for stage III endometrial cancer: a multicenter study, respectively. The same awards for poster 
presentation were given to Dr. Gwan Hee Han of Kyung Hee University for Expression of 
NANOG and AMPK modulate EOC progression through AMPK/mTOR signaling pathway and Dr. Dan-
Ah Chae of Chung-Ang University for Overexpressed gonadotrophin releasing hormone 2 is a poor 
prognostic factor of serous ovarian cancer. Dr. E Sun Paik of Sungkyunkwan University received the 
Best Paper Award of the Journal of Gynecologic Oncology for his work on Prediction of survival 
outcomes in patients with epithelial ovarian cancer using machine learning methods [28]. Drs. Gun Oh 
Chong of Kyungpook National University and Chel-Hun Choi of Sungkyunkwan University 
received the Best Reviewer Awards for their contribution to the journal.
CONCLUSION
The 36th Annual Meeting of the KSGO was the fully virtual meeting organized by the KSGO. This 
conference made the participants to learn the latest knowledge in various fields in one place.
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